ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

16.43
-0.72
( -4.20% )
Actualizado: 12:37:59

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
16.43
Postura de Compra
15.90
Postura de Venta
16.44
Volume Operado de la Acción
490,857
14.63 Rango del Día 16.82
7.4843 Rango de 52 semanas 29.82
Capitalización de Mercado [m]
Precio Anterior
17.15
Precio de Apertura
16.82
Última hora de negociación
12:36:02
Volumen financiero
US$ 7,846,247
Precio Promedio Ponderado
15.9848
Volumen promedio (3 m)
201,782
Acciones en circulación
17,615,040
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-11.26
Beneficio por acción (BPA)
-1.42
turnover
116.88M
Beneficio neto
-25.09M

Acerca de Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was US$17.15. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of US$ 7.4843 to US$ 29.82.

Rigel Pharmaceuticals currently has 17,615,040 shares in issue. The market capitalisation of Rigel Pharmaceuticals is US$302.10 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.26.

RIGL Últimas noticias

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 R289 was...

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/...

Rigel to Present at the Jefferies London Healthcare Conference

Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-3.27-16.598984771619.719.714.6318307217.30929169CS
4-9.5045-36.648094237425.934529.514.6319549621.80302153CS
120.150.92137592137616.2829.8213.570520178221.2646837CS
266.92872.91096611249.50229.827.484331147313.15826474CS
522.2315.704225352114.229.827.484379344412.37200717CS
156-11.87-41.943462897528.335.156.4216981113.78757117CS
260-5.17-23.935185185221.6556.4246239522.85596355CS

RIGL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Rigel Pharmaceuticals?
El precio actual de las acciones de Rigel Pharmaceuticals es US$ 16.43
¿Cuántas acciones de Rigel Pharmaceuticals están en circulación?
Rigel Pharmaceuticals tiene 17,615,040 acciones en circulación
¿Cuál es la capitalización de mercado de Rigel Pharmaceuticals?
La capitalización de mercado de Rigel Pharmaceuticals es USD 302.1M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Rigel Pharmaceuticals?
Rigel Pharmaceuticals ha negociado en un rango de US$ 7.4843 a US$ 29.82 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Rigel Pharmaceuticals?
El ratio precio/beneficio de Rigel Pharmaceuticals es -11.26
¿Cuál es el ratio de efectivo a ventas de Rigel Pharmaceuticals?
El ratio de efectivo a ventas de Rigel Pharmaceuticals es 2.42
¿Cuál es la moneda de reporte de Rigel Pharmaceuticals?
Rigel Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Rigel Pharmaceuticals?
El último ingresos anual de Rigel Pharmaceuticals es USD 116.88M
¿Cuál es el último beneficio anual de Rigel Pharmaceuticals?
El último beneficio anual de Rigel Pharmaceuticals es USD -25.09M
¿Cuál es la dirección registrada de Rigel Pharmaceuticals?
La dirección registrada de Rigel Pharmaceuticals es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Rigel Pharmaceuticals?
La dirección del sitio web de Rigel Pharmaceuticals es www.rigel.com
¿En qué sector industrial opera Rigel Pharmaceuticals?
Rigel Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.03M
HOURHour Loop Inc
US$ 4.40
(207.69%)
96.45M
GTIGraphjet Technology
US$ 0.61
(168.72%)
262.75M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.8M
AVGRAvinger Inc
US$ 1.45
(125.72%)
106.84M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.01M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.57M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.44M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.5M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.34k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
277.3M
GTIGraphjet Technology
US$ 0.61
(168.72%)
262.75M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
179.39M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
107.86M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
107.43M

RIGL Discussion

Ver más
dcaf7 dcaf7 8 meses hace
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 8 meses hace
RIGL under $2
👍️0
Monksdream Monksdream 9 meses hace
RIGL under $2
👍️0
dcaf7 dcaf7 9 meses hace
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 9 meses hace
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 10 meses hace
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 año hace
Rigl should be VTGN (Today) one day.
👍️0
bme bme 1 año hace
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 año hace
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 año hace
Better be good.
👍️0
bme bme 1 año hace
Ugly.
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
base
👍️0
bme bme 2 años hace
What a shoot! Amazing.
👍️0
bme bme 2 años hace
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 2 años hace
nice fins
👍️0
The Night Stalker The Night Stalker 2 años hace
gem
👍️0
The Night Stalker The Night Stalker 2 años hace
gem
👍️0
The Night Stalker The Night Stalker 2 años hace
easy
👍️0
bme bme 2 años hace
Nice spike AH today.
👍️0
bme bme 2 años hace
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 2 años hace
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 2 años hace
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 2 años hace
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
bme bme 2 años hace
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 2 años hace
quite the dip
👍️0
The Night Stalker The Night Stalker 2 años hace
ready
👍️0
The Night Stalker The Night Stalker 2 años hace
ready
👍️0
The Night Stalker The Night Stalker 2 años hace
red to green
👍️0
The Night Stalker The Night Stalker 2 años hace
red to green
👍️0
bme bme 2 años hace
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 años hace
beauty
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
bme bme 2 años hace
Expect Q4 filing this week?
👍️0
bme bme 2 años hace
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 años hace
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 años hace
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 años hace
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 años hace
RIGL news out
👍️0
bme bme 2 años hace
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 años hace
Just like ABQQ. Right?
👍️0
subslover subslover 2 años hace
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 años hace
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 años hace
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 años hace
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 años hace
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 años hace
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 años hace
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Su Consulta Reciente

Delayed Upgrade Clock